Shawna Shipman
Family · Cleveland, OKNPI 1639444532
Payments from drug & device makers
Across 154 payments — averaging $21.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$686
- Lilly USA, LLC$275
- Amgen$223
- GSK$197
- Sanofi-aventis U.S. LLC$119
- plus $728 from 17 others
What the payments were for
- Food & beverage$3,324100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 50 | $1,096 |
| AstraZeneca | 25 | $686 |
| Lilly USA, LLC | 16 | $275 |
| Amgen | 10 | $223 |
| GSK | 11 | $197 |
| Sanofi-aventis U.S. LLC | 1 | $119 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $111 |
| Novo Nordisk | 7 | $108 |
| Astellas Pharma US Inc | 4 | $103 |
| Merck | 5 | $82 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $46 |
| Sumitomo Pharma America, Inc. | 2 | $38 |
| Boehringer Ingelheim | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Pfizer | 2 | $30 |
| Lundbeck LLC | 1 | $22 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Novartis | 1 | $17 |
| Johnson & Johnson | 1 | $17 |
| Biogen | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,324 in reported general payments places this provider in the 90th percentile of 2,026 family providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 82 | $92,738 |
| OzempicSemaglutide | 49 | $50,271 |
| EliquisApixaban | 49 | $42,895 |
| FarxigaDapagliflozin Propanediol | 20 | $33,150 |
| JardianceEmpagliflozin | 18 | $30,024 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $24,869 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $23,369 |
| XareltoRivaroxaban | 28 | $19,635 |
| TrulicityDulaglutide | 20 | $19,442 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $17,637 |
| JanuviaSitagliptin Phosphate | 15 | $14,860 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $8,173 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $5,031 |
| SynthroidLevothyroxine Sodium | 34 | $3,621 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 89 | $3,358 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $275 | $112,180102 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $686 | $58,01952 claims |
| Novo NordiskOzempic | $108 | $50,27149 claims |
| PfizerEliquis | $30 | $42,89549 claims |
| Boehringer IngelheimJardiance | $37 | $30,02418 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $197 | $28,40134 claims |
| Johnson & JohnsonXarelto | $17 | $19,63528 claims |
| MerckJanuvia | $82 | $14,86015 claims |
| AbbVieSynthroid | $1,096 | $3,62134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,026 family providers in Oklahoma.
Other family in Cleveland
- April WilcoxOklahoma City$245K
- Jeremy MorganOklahoma City$63K
- Samantha BellingerOklahoma City$39K
- Candy WilliamsTulsa$22K
- Lacey HillOklahoma City$20K
- Shelby WrightStillwater$17K
- Brandy ReevesNorman$17K
- Amanda OblanderYukon$17K
- Julia John SamuelOklahoma City$17K
- Jillian OakleafTulsa$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.